Related references
Note: Only part of the references are listed.A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
Qianqian Ni et al.
SCIENCE ADVANCES (2020)
Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery
Zhi-Biao Wang et al.
VACCINES (2020)
The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice
Stefania Cuzzubbo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination
Jingyao Gan et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect
Wei-can Chen et al.
FRONTIERS IN IMMUNOLOGY (2020)
A review of cancer immunotherapy: from the past, to the present, to the future
K. Esfahani et al.
CURRENT ONCOLOGY (2020)
Design of an innovative platform for the treatment of cerebral tumors by means of erythro-magneto-HA-virosomes
Gioia Lucarini et al.
BIOMEDICAL PHYSICS & ENGINEERING EXPRESS (2020)
Therapeutic cancer vaccine: building the future from lessons of the past
T. Tran et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Adapting liposomes for oral drug delivery
Haisheng He et al.
ACTA PHARMACEUTICA SINICA B (2019)
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2019)
Polymers for subunit vaccine delivery
Reshma J. Nevagi et al.
EUROPEAN POLYMER JOURNAL (2019)
Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication
Sean K. Maynard et al.
BMC CANCER (2019)
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma
Yi Zheng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses
Stephen N. Crooke et al.
EXPERIMENTAL GERONTOLOGY (2019)
Codelivery of mRNA with α-Galactosylceramide Using a New Lipopolyplex Formulation Induces a Strong Antitumor Response upon Intravenous Administration
Maria L. Guevara et al.
ACS OMEGA (2019)
Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances
Hatem A. F. M. Hassan et al.
JOURNAL OF CONTROLLED RELEASE (2019)
A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+T cells and anti-tumor immunity
Lauren Zebertavage et al.
PLOS ONE (2019)
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Karim Vermaelen
FRONTIERS IN IMMUNOLOGY (2019)
Intranasal Administration of miR-146a Agomir Rescued the Pathological Process and Cognitive Impairment in an AD Mouse Model
Hui Mai et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Metallic nanoparticles for cancer immunotherapy
Emily Reiser Evans et al.
MATERIALS TODAY (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Personalized cancer vaccines: adjuvants are important, too
Cecile Gouttefangeas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Current challenges for cancer vaccine adjuvant development
William S. Bowen et al.
EXPERT REVIEW OF VACCINES (2018)
Radiation therapy and immunotherapy: what is the optimal timing or sequencing?
Maureen L. Aliru et al.
IMMUNOTHERAPY (2018)
Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System
Erika A. K. Fletcher et al.
JOURNAL OF IMMUNOLOGY (2018)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Brigitte Dreno et al.
LANCET ONCOLOGY (2018)
Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses
Sara M. Mangsbo et al.
MOLECULAR IMMUNOLOGY (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy
Gella Maelys Ngandeu Neubi et al.
BIOMATERIALS SCIENCE (2018)
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial
Poulam M. Patel et al.
ONCOIMMUNOLOGY (2018)
An RNA toolbox for cancer immunotherapy
Fernando Pastor et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma
Jennifer L. McQuade et al.
BMC CANCER (2018)
A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model
Sangkyu Park et al.
ONCOTARGETS AND THERAPY (2018)
Toll-Like Receptor 3 Stimulation Triggers Metabolic Reprogramming in Pharyngeal Cancer Cell Line Through Myc, MAPK, and HIF
Tanja Matijevic Glavan et al.
MOLECULAR CARCINOGENESIS (2017)
Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study
Renata Ursu et al.
EUROPEAN JOURNAL OF CANCER (2017)
Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens
Jie Gao et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses
Alice Gutjahr et al.
JOURNAL OF IMMUNOLOGY (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Carbon nanotubes: A review of novel strategies for cancer diagnosis and treatment
Mojgan Sheikhpour et al.
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2017)
The Effect of Superparamagnetic Iron Oxide Nanoparticle Surface Charge on Antigen Cross-Presentation
Yongbin Mou et al.
NANOSCALE RESEARCH LETTERS (2017)
Signalling strength determines proapoptotic functions of STING
Muhammet F. Gulen et al.
NATURE COMMUNICATIONS (2017)
The Effect of Superparamagnetic Iron Oxide Nanoparticle Surface Charge on Antigen Cross-Presentation
Yongbin Mou et al.
NANOSCALE RESEARCH LETTERS (2017)
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
Caroline Tosch et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses
Antoine F. Carpentier et al.
PLOS ONE (2017)
Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases
Mark B. Faries et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants
Robyn Marty-Roix et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Safety and tolerability evaluation of the use of Montanide ISA (TM) 51 as vaccine adjuvant: A systematic review
Eva van Doorn et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma
Christoph Hoeller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution
Line Pedersen et al.
CELL METABOLISM (2016)
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
Pedro C. Rodriguez et al.
CLINICAL CANCER RESEARCH (2016)
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
Mutsunori Murahashi et al.
CLINICAL IMMUNOLOGY (2016)
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin
Samantha Cambier et al.
EUROPEAN UROLOGY (2016)
Vaccine adjuvants as potential cancer immunotherapeutics
Burcu Temizoz et al.
INTERNATIONAL IMMUNOLOGY (2016)
Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1 BBL
Roni Engelstein et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan F. Vansteenkiste et al.
LANCET ONCOLOGY (2016)
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Elisabeth Quoix et al.
LANCET ONCOLOGY (2016)
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2016)
Butyrate production from high-fiber diet protects against lymphoma tumor
Wei Wei et al.
LEUKEMIA & LYMPHOMA (2016)
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz et al.
NATURE (2016)
Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology
Amy K. LeBlanc et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment
Fabian Flores-Borja et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment
Shijin Xia et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Adjuvants: Classification, Modus Operandi, and Licensing
Juliana de Souza Apostolico et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope
P. Baumgaertner et al.
ONCOIMMUNOLOGY (2016)
Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8+ and CD4+ T Cells
Wenjie Yin et al.
EBIOMEDICINE (2016)
Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8+ T Cells that Protect Against Subcutaneous B16-OVA Melanoma
Felicity C. Stark et al.
VACCINES (2016)
Polyelectrolyte Multilayers Assembled Entirely from Immune Signals on Gold Nanoparticle Templates Promote Antigen-Specific T Cell Response
Peipei Zhang et al.
ACS NANO (2015)
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L. Apetoh et al.
ANNALS OF ONCOLOGY (2015)
Sipuleucel-T (Provenge®)-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention
Szymon Jaroslawski et al.
BIODRUGS (2015)
Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model
Maria Tagliamonte et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Synthetic Nanoparticles for Vaccines and Immunotherapy
Darrell J. Irvine et al.
CHEMICAL REVIEWS (2015)
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
Alexander Filatenkov et al.
CLINICAL CANCER RESEARCH (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
G. Giaccone et al.
EUROPEAN JOURNAL OF CANCER (2015)
Nanoparticu late STING agonists are potent lymph node-targeted vaccine adjuvants
Melissa C. Hanson et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)
David H. Lawson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model
Joana M. Silva et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Naive T Cell Maintenance and Function in Human Aging
Joerg J. Goronzy et al.
JOURNAL OF IMMUNOLOGY (2015)
Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer
Michele Mondini et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Microneedle-assisted dendritic cell-targeted nanoparticles for transcutaneous DNA immunization
Ying Hu et al.
POLYMER CHEMISTRY (2015)
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine
Todd Bartkowiak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Microenvironment abnormalities and lymphomagenesis: Immunological aspects
Joseph G. Taylor et al.
SEMINARS IN CANCER BIOLOGY (2015)
Vaccines, Adjuvants, and Dendritic Cell Activators-Current Status and Future Challenges
Joseph Obeid et al.
SEMINARS IN ONCOLOGY (2015)
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
Neil L. Berinstein et al.
ONCOIMMUNOLOGY (2015)
Cytomegalovirus Infection and Memory T Cell Inflation
Jihye Kim et al.
Immune Network (2015)
A phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
Dan P. Zandberg et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
Hideho Okada et al.
CLINICAL CANCER RESEARCH (2015)
Cancer vaccine adjuvants - recent clinical progress and future perspectives
Abid H. Banday et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2015)
Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease
Yong Taik Lim
CLINICAL AND EXPERIMENTAL VACCINE RESEARCH (2015)
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Yuchen Fan et al.
VACCINES (2015)
Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment
Hanqing Liu et al.
ACTA PHARMACEUTICA (2015)
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Kevin C. Soares et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Nanoparticle-Delivered Transforming Growth Factor-β siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment
Zhenghong Xu et al.
ACS NANO (2014)
The effect of combined IL10 siRNA and CpG ODN as pathogenmimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma
Pallab Pradhan et al.
BIOMATERIALS (2014)
Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy
Eiji Yuba et al.
BIOMATERIALS (2014)
P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
Sheida Shariat et al.
CANCER LETTERS (2014)
Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody
Lavakumar Karyampudi et al.
CANCER RESEARCH (2014)
A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
Sailyn Alfonso et al.
CLINICAL CANCER RESEARCH (2014)
TLR5-Mediated Sensing of Gut Microbiota Is Necessary for Antibody Responses to Seasonal Influenza Vaccination
Jason Z. Oh et al.
IMMUNITY (2014)
Targeting human dendritic cells in situ to improve vaccines
Kartik Sehgal et al.
IMMUNOLOGY LETTERS (2014)
Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma A Randomized Clinical Trial
F. Stephen Hodi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
Ronald Levy et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Designing and building the next generation of improved vaccine adjuvants
Luis A. Brito et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study
Luis J. Cruz et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8+ T cell responses
Salka Keller et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Aging and Cytomegalovirus Infection Differentially and Jointly Affect Distinct Circulating T Cell Subsets in Humans
Anne M. Wertheimer et al.
JOURNAL OF IMMUNOLOGY (2014)
Vaccination With NY- ESO-1 Overlapping Peptides Mixed With Picibanil OK-432 and Montanide ISA-51 in Patients With Cancers Expressing the NY- ESO-1 Antigen
Hisashi Wada et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts et al.
LANCET ONCOLOGY (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
Octaarginine-Modified Liposomes Enhance Cross-Presentation by Promoting the C-Terminal Trimming of Antigen Peptide
Takashi Nakamura et al.
MOLECULAR PHARMACEUTICS (2014)
Tracking Targeted Bimodal Nanovaccines: Immune Responses and Routing in Cells, Tissue, and Whole Organism
Luis J. Cruz et al.
MOLECULAR PHARMACEUTICS (2014)
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity
Kyle K. L. Phua et al.
SCIENTIFIC REPORTS (2014)
Gold Nanoparticles Displaying Tumor-Associated Self-Antigens as a Potential Vaccine for Cancer Immunotherapy
Sukyung Ahn et al.
ADVANCED HEALTHCARE MATERIALS (2014)
Adjuvants and myeloid-derived suppressor cells: Enemies or allies in therapeutic cancer vaccination
Audry Fernandez et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7
Christopher B. Fox et al.
JOURNAL OF NANOBIOTECHNOLOGY (2014)
Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival
William E. Carson et al.
CANCER IMMUNOLOGY RESEARCH (2014)
STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Dinesh Chandra et al.
CANCER IMMUNOLOGY RESEARCH (2014)
pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory Oligonucleotides
John T. Wilson et al.
ACS NANO (2013)
Engineering an Effective Immune Adjuvant by Designed Control of Shape and Crystallinity of Aluminum Oxyhydroxide Nanoparticles
Bingbing Sun et al.
ACS NANO (2013)
Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
Ursula Wiedermann et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide
Elise P. Salerno et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response
Chiara Camisaschi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J. Pienta et al.
INVESTIGATIONAL NEW DRUGS (2013)
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
Wim H. J. Kruit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study
Paul Sabbatini et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration
Takashi Nakamura et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Immune system targeting by biodegradable nanoparticles for cancer vaccines
Joana M. Silva et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
Jeffrey M. Hardacre et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
TLR agonists: our best frenemy in cancer immunotherapy
Sabina Kaczanowska et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
Mariette I. E. van Poelgeest et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael et al.
NATURE MEDICINE (2013)
Alginic Acid-Coated Chitosan Nanoparticles Loaded with Legumain DNA Vaccine: Effect against Breast Cancer in Mice
Ze Liu et al.
PLOS ONE (2013)
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose
Alexandre de Titta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial
Nuhad K. Ibrahim et al.
JOURNAL OF CANCER (2013)
When aging reaches CD4+T-cells: phenotypic and functional changes
Marco Antonio Moro-Garcia et al.
FRONTIERS IN IMMUNOLOGY (2013)
Mechanism of immunopotentiation and safety of aluminum adjuvants
Harm HogenEsch
FRONTIERS IN IMMUNOLOGY (2013)
Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma
Sojun Hoshimoto et al.
ANNALS OF SURGERY (2012)
Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes
Evan A. Scott et al.
BIOMATERIALS (2012)
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
Juergen C. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses
Kentaro Sumida et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice
Ming Yang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
The application of Toll like receptors for cancer therapy
Eui Young So et al.
International Journal of Biological Sciences (2012)
Expression profiles of Toll-like receptors in non-small cell lung, cancer and idiopathic pulmonary fibrosis
Katerina D. Samara et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Physical Activity, Biomarkers, and Disease Outcomes in Cancer Survivors: A Systematic Review
Rachel Ballard-Barbash et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
Neil L. Berinstein et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Signaling pathways in aged T cells - A reflection of T cell differentiation, cell senescence and host environment
Joerg J. Goronzy et al.
SEMINARS IN IMMUNOLOGY (2012)
CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-κB activation and NO production
Xiaoli Li et al.
TUMOR BIOLOGY (2012)
The convergence of radiation and immunogenic cell death signaling pathways
Encouse B. Golden et al.
FRONTIERS IN ONCOLOGY (2012)
Cross-presentation by dendritic cells
Olivier P. Joffre et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Expression of Toll-Like Receptors on Breast Tumors: Taking a Toll on Tumor Microenvironment
Debika Bhattacharya et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2012)
Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity
Aishwarya Sridharan et al.
AGE (2011)
Impact of aging on dendritic cell functions in humans
Anshu Agrawal et al.
AGEING RESEARCH REVIEWS (2011)
Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
Juergen Kuball et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth
Zhenyu Cai et al.
CANCER RESEARCH (2011)
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2011)
Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
Tomasz M. Beer et al.
CLINICAL CANCER RESEARCH (2011)
NRAMP1 and hGPX1 Gene Polymorphism and Response to Bacillus Calmette-Guerin Therapy for Bladder Cancer
Edmund Chiong et al.
EUROPEAN UROLOGY (2011)
Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer
Govind Ragupathi et al.
EXPERT REVIEW OF VACCINES (2011)
Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk
Anton G. Kutikhin
HUMAN IMMUNOLOGY (2011)
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
Charles Butts et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Sid P. Kerkar et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma
Stephen J. Schuster et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improvement of different vaccine delivery systems for cancer therapy
Azam Bolhassani et al.
MOLECULAR CANCER (2011)
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
Elisabeth Quoix et al.
LANCET ONCOLOGY (2011)
Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA
Federico Perche et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2011)
Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics
Dan Shu et al.
NATURE NANOTECHNOLOGY (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
David Miles et al.
ONCOLOGIST (2011)
Induction of TLR-2 and TLR-5 Expression by Helicobacter pylori Switches cagPAI-Dependent Signalling Leading to the Secretion of IL-8 and TNF-α
Suneesh Kumar Pachathundikandi et al.
PLOS ONE (2011)
Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells
Megan K. L. MacLeod et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus, the TLR3 agonist poly(I:C)
Darin A. Wick et al.
VACCINE (2011)
Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy
Saul J. Priceman et al.
BLOOD (2010)
TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients
Chao Wang et al.
BMC CANCER (2010)
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
Ursula Wiedermann et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
Xia Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma
Chiara Brignole et al.
CANCER RESEARCH (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination
Kanako Iseki et al.
CANCER SCIENCE (2010)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi et al.
CLINICAL CANCER RESEARCH (2010)
Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
Srinivas Nagaraj et al.
CLINICAL CANCER RESEARCH (2010)
Functional cell surface expression of Toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas
Junichiro Tanaka et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2010)
A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice
Zhenghua Zhong et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)
Impaired Functions of Peripheral Blood Monocyte Subpopulations in Aged Humans
Joseph Nyugen et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance
Julien Cherfils-Vicini et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens
Sarah L. Jongbloed et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipeptide Melanoma Vaccines
Craig L. Slingluff et al.
JOURNAL OF IMMUNOTHERAPY (2010)
A Phase 2 Trial of Immunotherapy With Mitumprotimut-T (Id-KLH) and GM-CSF Following Rituximab in Follicular B-cell Lymphoma
Omer N. Koc et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis
Jochen T. Schaefer et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Targeting Toll-like receptors: emerging therapeutics?
Elizabeth J. Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
Alexandre Carpentier et al.
NEURO-ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
Marij J. P. Welters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Claire Banissi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects
Hyun-Il Cho et al.
CANCER RESEARCH (2009)
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
Mark B. Faries et al.
CLINICAL CANCER RESEARCH (2009)
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
Craig L. Slingluff et al.
CLINICAL CANCER RESEARCH (2009)
Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas
Camilla Rydberg et al.
IMMUNOLOGY (2009)
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
Arnold Freedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Antibodies designed as effective cancer vaccines
R. L. Metheringham et al.
MABS (2009)
Self-assembly of DNA into nanoscale three-dimensional shapes
Shawn M. Douglas et al.
NATURE (2009)
Infection-mimicking materials to program dendritic cells in situ
Omar A. Ali et al.
NATURE MATERIALS (2009)
Toll-like receptors and cancer
Seth Rakoff-Nahoum et al.
NATURE REVIEWS CANCER (2009)
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer
Andrew Bottomley et al.
EUROPEAN JOURNAL OF CANCER (2008)
Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer
Sang Hoon Rhee et al.
GASTROENTEROLOGY (2008)
EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results
A. M. Eggermont et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome
Mirjam Kool et al.
JOURNAL OF IMMUNOLOGY (2008)
An adjuvant autologous therapeutic vaccine (HSPPC-96 vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentrel, open-label, randomised phase III trial
Christopher Wood et al.
LANCET (2008)
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Stephanie C. Eisenbarth et al.
NATURE (2008)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Ronald J. Buckanovich et al.
NATURE MEDICINE (2008)
Role of Toll-like receptors in gastrointestinal malignancies
M. Fukata et al.
ONCOGENE (2008)
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
Harry Sokol et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The toll-like receptor pathway: A novel mechanism of infection-induced carcinogenesis of prostate epithelial cells
Shilajit D. Kundu et al.
PROSTATE (2008)
Dual topology, of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: Differential signaling mechanisms of TLR3-induced NF-κB activation and apoptosis
Kentaro Yoneda et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2008)
Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections
Janko Nikolich-Zugich
NATURE REVIEWS IMMUNOLOGY (2008)
Mechanisms linking physical activity with cancer
Anne McTiernan
NATURE REVIEWS CANCER (2008)
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity
Martijn S. Bijker et al.
JOURNAL OF IMMUNOLOGY (2007)
A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder
S. J. Harland et al.
JOURNAL OF UROLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
PANVAC™-VF:: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
Ravi A. Madan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells
David F. LaRosa et al.
IMMUNOLOGY LETTERS (2007)
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
G. Parmiani et al.
ANNALS OF ONCOLOGY (2007)
Age-associated defect in human TLR-1/2 function
David van Duin et al.
JOURNAL OF IMMUNOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation
Andrew E. Gelman et al.
IMMUNITY (2006)
Clinical applications of virosomes in cancer immunotherapy
Michel Adamina et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
John Nemunaitis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
SJ Antonia et al.
CLINICAL CANCER RESEARCH (2006)
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial
SM Di Stasi et al.
LANCET ONCOLOGY (2006)
A fundamental bimodal role for neuropeptide Y1 receptor in the immune system
J Wheway et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Combining radiotherapy and immunotherapy: A revived partnership
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis
E Bryl et al.
ARTHRITIS AND RHEUMATISM (2005)
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-0897113; Silva Study)
G Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer
C Butts et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Direct stimulation of human T cells via TLR5 and TLR7/8:: Flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells
G Caron et al.
JOURNAL OF IMMUNOLOGY (2005)
Diversity of the human intestinal microbial flora
PB Eckburg et al.
SCIENCE (2005)
Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells:: An implication for interaction with Helicobacter pylori
B Schmausser et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2005)
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN
CL Ahonen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01
RE Smith et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen
SS Neelapu et al.
CLINICAL CANCER RESEARCH (2004)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Tumor necrosis factor-α and CD80 modulate CD28 expression through a similar mechanism of T-cell receptor-independent inhibition of transcription
DE Lewis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Toll-like receptor ligands directly promote activated CD4+ T cell survival
AE Gelman et al.
JOURNAL OF IMMUNOLOGY (2004)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
M Chakraborty et al.
JOURNAL OF IMMUNOLOGY (2003)
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma
J Weber et al.
CANCER (2003)
Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice
E Seki et al.
JOURNAL OF IMMUNOLOGY (2002)
Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria
G Jan et al.
CELL DEATH AND DIFFERENTIATION (2002)
Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals
JJ Goronzy et al.
JOURNAL OF VIROLOGY (2001)
Probiotic bacteria enhance murine and human intestinal epithelial barrier function
K Madsen et al.
GASTROENTEROLOGY (2001)
IFN-γ-dependent transcription of MHC class IIIA is impaired in macrophages from aged mice
C Herrero et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Share Paper
